Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF STR in treatment‑naive HIV‑1 infected adolescents
2015-000313-40Phase 2
- Sponsor
- Gilead Sciences
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Primary endpoint: Antiviral activity through Week 48 in Part A.
02
Drugs
emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-000313-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000313-40.